Zydus Lifesciences Ltd Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 17 Jul 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹1.1L Cr
India business is expected to track double-digit growth for the next 2-3 years, driven by innovative brands, GLP-1 launches, and new proprietary drugs (Page 16). The company expects continued strong growth in revenues and earnings driven by multiple business segments including pharmaceuticals, specialty, biosimilars, and vaccines.
From Zydus Lifesciences Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹1,120
Market Cap
₹1.1L Cr
P/E Ratio
23.3
How does Zydus Lifesciences Ltd rank in Pharmaceuticals & Biotechnology?
Compare Zydus Lifesciences Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Zydus Lifesciences Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹7.6K Cr, net profit ₹1.3K Cr.
Full financials →📊 Revenue & Sales Performance
- →India business is expected to track double-digit growth for the next 2-3 years, driven by innovative brands, GLP-1 launches, and new proprietary drugs (Page 16).
- →US business projected to grow despite loss of Revlimid sales; volume growth recorded at 11% with plans to launch 40-45+ products in FY27 including exclusives and biosimilars (Pages 12, 13, 17).
- →Specialty and 505(b)(2) product pipeline in the US to contribute significantly alongside biosimilars and the Ranibizumab launch (Page 17).
- →International markets expected to continue strong growth (~20% plus) due to focus on branded space and portfolio expansion in emerging markets (Page 11).
- →Biosimilar launches like Ranibizumab and specialty drugs such as Zycubo to support further growth (Pages 16, 17).
- →Vaccines business aims for over ₹1,000 crore in next 3-4 years, with strong tender wins already impacting sales (Page 15).
📈 Profitability & Margins
- →The company expects continued strong growth in revenues and earnings driven by multiple business segments including pharmaceuticals, specialty, biosimilars, and vaccines.
- →FY27 and beyond are expected to show robust growth with several large product launches lined up in the US, including exclusive specialty and 505(b)(2) products.
- →Operating margins are expected to remain healthy around 23% plus, despite the gradual decline in high-margin Lenalidomide sales and integration costs from acquisitions (Amplitude, Comfort Click).
- →R&D spend will remain steady at about 7.5%-8% of revenue, with some lumpiness due to clinical trials but contributing to long-term pipeline growth.
- →International markets and specialty biologics are key growth drivers, with biosimilar launches and evolving commercial teams adding momentum.
- →Growth boosters like Saroglitazar and Desidustat are expected to enhance India business, sustaining potential double-digit growth for 2-3 years.
- →The company targets building its vaccine business to ₹1000+ crore in 3-4 years, driving diversification and profitability.
🏗️ Capital Expenditure Plans
- →Zydus is investing in scaling up its Bio CDMO business, which will take 2-3 years to become meaningful, with optimism based on progress in clinical and regulatory milestones, especially for BOT, BAL facilities (Page 8).
- →Commercialization of the CDMO business is expected to start in the second half of FY27, with revenues ramping up alongside facility qualifications (Page 7-8).
- →The recent acquisitions like Amplitude Surgical and Comfort Click are part of strategic investments aiding long-term growth and margin diversification (Page 5).
- →Plans exist for a future commercial team for Saroglitazar (Saro), indicating upcoming commercial and launch-related investments though not yet factored into current OPEX (Page 20).
- →Continued strong R&D investments are indicated, targeting around 7.5%-8% of revenue for FY26, supporting pipeline development including 505(b)(2) products and biosimilars (Pages 7, 9).
💰 Fundraising & Capital Structure
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were Zydus Lifesciences Ltd Q3 FY26 results?
India business is expected to track double-digit growth for the next 2-3 years, driven by innovative brands, GLP-1 launches, and new proprietary drugs (Page 16). The company expects continued strong growth in revenues and earnings driven by multiple business segments including pharmaceuticals, specialty, biosimilars, and vaccines.
What is Zydus Lifesciences Ltd share price analysis?
Zydus Lifesciences Ltd currently shows a neutral. The stock trades at a P/E of 23.3 with a market cap of ₹113,237 Cr. Investors should review the full earnings analysis for detailed insights.
Is Zydus Lifesciences Ltd planning capital expenditure?
Zydus is investing in scaling up its Bio CDMO business, which will take 2-3 years to become meaningful, with optimism based on progress in clinical and regulatory milestones, especially for BOT, BAL facilities (Page 8).
Keep Zydus Lifesciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.